[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Scanu et al., 1990 - Google Patents

Lipoprotein (a). Heterogeneity and biological relevance.

Scanu et al., 1990

View PDF
Document ID
17944848717081479675
Author
Scanu A
Fless G
et al.
Publication year
Publication venue
The Journal of clinical investigation

External Links

Snippet

Lipoprotein (a), or Lp (a),'discovered by KAre Berg (1) more than 25 years ago, remains today a fascinating subject of research both because of its presumed association with athero- sclerotic cardiovascular disease (ASCVD)(2-14) and the many challenges it is offering to …
Continue reading at www.jci.org (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/60—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving cholesterol
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes

Similar Documents

Publication Publication Date Title
Scanu et al. Lipoprotein (a). Heterogeneity and biological relevance.
Connelly et al. Hepatic lipase deficiency
Marcovina et al. Lipoprotein (a) as a risk factor for coronary artery disease
Ellis et al. The renaissance of lipoprotein (a): brave new world for preventive cardiology?
Hegele et al. Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics.
Scanu Lipoprotein (a): a genetic risk factor for premature coronary heart disease
Faustinella et al. Catalytic triad residue mutation (Asp156—-Gly) causing familial lipoprotein lipase deficiency. Co-Inheritance with a nonsense mutation (Ser447—-Ter) in a Turkish family
Nielsen Atherogenecity of lipoprotein (a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux
Stahlberg et al. Hepatic cholesterol metabolism in human obesity
Martínez‐Arranz et al. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
Brodt-Eppley et al. Plasma cholesterol esterase level is a determinant for an atherogenic lipoprotein profile in normolipidemic human subjects
Porkka et al. Phenotype expression in familial combined hyperlipidemia
Duriez et al. High-density lipoprotein subclasses and apolipoprotein AI
Breckenridge et al. Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-11 deficiency
Werba et al. Plasma triglycerides and lipoprotein (a): inverse relationship in a hyperlipidemic Italian population
Kwiterovich Jr Diagnosis and management of familial dyslipoproteinemia in children and adolescents
Scanu The role of lipoprotein (a) in the pathogenesis of atherosclerotic cardiovascular disease and its utility as predictor of coronary heart disease events
Auwerx et al. Coexistence of abnormalities of hepatic lipase and lipoprotein lipase in a large family.
Takata et al. A new case of apoA-I deficiency showing codon 8 nonsense mutation of the apoA-I gene without evidence of coronary heart disease
Milosavljevic et al. VLDL-induced triglyceride accumulation in human macrophages is mediated by modulation of LPL lipolytic activity in the absence of change in LPL mass
Kottke Lipid markers for atherosclerosis
Ebara et al. No evidence of accelerated atherosclerosis in a 66-yr-old chylomicronemia patient homozygous for the nonsense mutation (Tyr61→ stop) in the lipoprotein lipase gene
Hamsten Triglycerides and coronary heart disease-has epidemiology given us the right answer? Anders Hamsten and Fredrik Karpe
Gómez et al. Influence of the− 514C/T polymorphism in the promoter of the hepatic lipase gene on postprandial lipoprotein metabolism
Scanu Genetic basis and pathophysiological implications of high plasma Lp (a) levels